Seeing Is Believing
Currently out of the existing stock ratings of Jason Gerberry, 173 are a BUY (65.04%), 63 are a HOLD (23.68%), 30 are a SELL (11.28%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 61.85% that have a potential upside of 29.43% achieved within 297 days.
Jason Gerberry’s has documented 558 price targets and ratings displayed on 56 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 22-Sep-2025.
Analyst best performing recommendations are on PROK (PROKIDNEY CORP.).
The best stock recommendation documented was for PROK (PROKIDNEY CORP.) at 6/30/2025. The price target of $1 was fulfilled within 8 days with a profit of $0.41 (69.49%) receiving and performance score of 86.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$284
$53.5 (23.21%)
$220
2 days ago
(10-Oct-2025)
43/44 (97.73%)
$53.5 (23.21%)
593
Hold
$251
$20.5 (8.89%)
$205
9 days ago
(03-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$39.5 (17.14%)
$195
25 days ago
(17-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Buy
$235
$4.5 (1.95%)
$200
26 days ago
(16-Sep-2025)
14/14 (100%)
$18.74 (8.67%)
483
Buy
$245
$14.5 (6.29%)
$210
27 days ago
(15-Sep-2025)
16/17 (94.12%)
$27.39 (12.59%)
244
Which stock is Jason Gerberry is most bullish on?
Which stock is Jason Gerberry is most reserved on?
What Year was the first public recommendation made by Jason Gerberry?